Abvc biopharma receives $50,000 in incremental licensing fees, boosting total payments to $346,000 from its three strategic partners

Fremont, calif., oct. 22, 2024 (globe newswire) -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, cns (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from aibtl biopharma inc. with this payment, abvc has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. abvc has received 23m aibtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100m after the product launches.
ABVC Ratings Summary
ABVC Quant Ranking